• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/13/25 4:10:10 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    Generation Bio Co._March 13, 2025
    0001733294false00017332942025-03-132025-03-13

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): March 13, 2025

    Generation Bio Co.

    (Exact Name of Registrant as Specified in Charter)

    ​

    Delaware

        

    001-39319

        

    81-4301284

    (State or Other Jurisdiction

    of Incorporation)

    ​

    (Commission

    File Number)

    ​

    (IRS Employer

    Identification No.)

    ​

    ​

    301 Binney Street

    Cambridge, MA

        

    02142 

    (Address of Principal Executive Offices)

    ​

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (617) 655-7500

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ​

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ​

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ​

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ​

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

    ​

    GBIO

    ​

    Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition.

    On March 13, 2025, Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

    The information in this Item 2.02 on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

    ​

    ​

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    No.

      

    Description

    99.1

      

    Press Release Issued by Generation Bio Co. on March 13, 2025.

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    GENERATION BIO CO.

    Date: March 13, 2025

    By:

    /s/ Geoff McDonough

    Name: Geoff McDonough, M.D.

    Title: President and Chief Executive Officer

    ​

    ​

    ​

    Get the next $GBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

      -  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid-2025 -  Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results."Our selective, redosable cell-targeted lipid nanoparticle (ctLNP) delivery syste

      5/7/25 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

      CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.   About Generation Bio Generation Bio is a biotechnology company working to chan

      4/2/25 6:59:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      -  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases -  Lead target and indication to be announced MY 2025 -  Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. "Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a

      3/13/25 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

      Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

      2/6/25 5:00:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

      Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea

      5/10/23 4:15:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

      CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th

      4/5/23 7:30:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    SEC Filings

    See more
    • SEC Form S-8 filed by Generation Bio Co.

      S-8 - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:21:11 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Generation Bio Co.

      10-Q - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:15:25 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:10:12 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      12/9/24 6:18:02 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      11/14/24 1:22:38 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/14/24 10:03:03 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Generation Bio downgraded by TD Cowen

      TD Cowen downgraded Generation Bio from Outperform to Market Perform

      10/19/23 7:43:32 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Generation Bio with a new price target

      Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00

      11/8/22 6:17:49 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Generation Bio with a new price target

      JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously

      12/15/21 7:17:06 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Samayoa Phillip converted options into 1,147 shares and covered exercise/tax liability with 337 shares, increasing direct ownership by 0.63% to 128,519 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:20 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Mcdonough Geoff covered exercise/tax liability with 1,548 shares and converted options into 5,274 shares, increasing direct ownership by 0.28% to 1,349,664 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:18 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF OPERATING OFFICER Paone Antoinette converted options into 1,592 shares and covered exercise/tax liability with 468 shares, increasing direct ownership by 5% to 23,082 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:13 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/14/25 4:05:17 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/11/23 4:30:19 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/6/23 4:30:13 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care